Pure Global
NCT06266910

Effects of Autostereoscopic 3D Visual Training on Binocular Vision Function of Myopes

Exploring the Effects of Autostereoscopic 3D Visual Training on Binocular Vision Function of Myopes Based on EEG and fNIRS
Zhongshan Ophthalmic Center, Sun Yat-sen University·ClinicalTrials.gov·otherNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Myopia
Drug/Device/Intervention
Visual training video
Study type
Interventional
Intervention type
other
Sponsor & location
Primary sponsor
Zhongshan Ophthalmic Center, Sun Yat-sen University
Location
Guangzhou, China
Timeline & enrollment
Phase
N/A
Start date
Feb 15, 2024
End date
Oct 10, 2024
Enrollment
80 participants
Primary outcome

Accommodative facility,Vergence facility

Summary

This study intends to conduct a relatively comprehensive binocular visual function
 examination and follow-up on two groups of myopic subjects, one receiving autostereoscopic 3D
 vision training and the other receiving 2D vision training as a control. The aim is to
 explore the impact of autostereoscopic 3D vision training on the accommodation and
 convergence functions of myopes. Additionally, synchronized EEG-fNIRS signals will be
 collected to investigate whether changes in binocular visual function are accompanied by
 corresponding alterations in brain function.

ICD-10 classifications
MyopiaDegenerative myopiaAmblyopia ex anopsiaOcular myiasisMyiasis
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06266910
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06266910 through Pure Global AI's free database. This phase not specified trial is sponsored by Zhongshan Ophthalmic Center, Sun Yat-sen University and is currently Not yet recruiting. The study focuses on Myopia. Target enrollment is 80 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.